Are you over 18 and want to see adult content?
More Annotations
A complete backup of strictlygeekproject.com
Are you over 18 and want to see adult content?
A complete backup of sewalittlelove.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of mistral-online.com
Are you over 18 and want to see adult content?
A complete backup of vintage-ads.livejournal.com
Are you over 18 and want to see adult content?
A complete backup of nbstevonnie.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of andersonmeneghesso.wordpress.com
Are you over 18 and want to see adult content?
Favourite Annotations
Kitchen Doors & Cabinets | Bedroom Wardrobes & Doors
Are you over 18 and want to see adult content?
DataXstream - SAP Integration, Consulting, and Solutions
Are you over 18 and want to see adult content?
EthereumClix - Ethereum Paid To Click Service
Are you over 18 and want to see adult content?
Фаркопы, рейлинги, багажники и комплектующие с доставкой по России
Are you over 18 and want to see adult content?
Buy Reverse Backconnect and Dedicated Proxy - Storm Proxies
Are you over 18 and want to see adult content?
志摩マリンレジャー|鳥羽・賢島のクルージング・イルカ島観光
Are you over 18 and want to see adult content?
Furniture, Mattresses, Home Decor, Bedding, Bath - JYSK Canada
Are you over 18 and want to see adult content?
Home - Upper Crust Pizza Co. | Jonesboro, Arkansas
Are you over 18 and want to see adult content?
Praxis-Magazin für Musiker | SOUND & RECORDING
Are you over 18 and want to see adult content?
Clipartix - Wonderful clipart gallery for your projects
Are you over 18 and want to see adult content?
Text
VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
MATTERHORN BIOSCIENCES Matterhorn is a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins. TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
MATTERHORN BIOSCIENCES Matterhorn is a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins. TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. OFFICES | VERSANT VENTURES Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.DISCOVERY ENGINES
Ridgeline, Versant’s Discovery Engine based in Switzerland, became operational in 2017 and has deployed resources to launch severalcompanies derived
TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
QUANTICEL PHARMACEUTICALS Quanticel's technology is based on the work of Stanford researchers and company founders Stephen Quake and Michael Clarke. Versant had backed other genomic technologies invented by Quake, and moved quickly to incubate Quanticel in 2010, shortly after the company was founded.VERSANT VENTURES
Outcome. In December 2014, Northern Biologics officially launched with $45 million in committed funding from Versant and Celgene, secure foundational IP licenses, a well-developed R&D plan and the basis for a strong management and scientific team. In December 2016, the Versant team enabled Northern Biologics to execute a transformative deal TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
TEAM | VERSANT VENTURES | BRIAN ATWOOD | VERSANT VENTURES Brian Atwood is a Managing Director specializing in biotechnology investing at Versant. Prior to co-founding Versant, he spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. He also has more than 15 years of operating experience in thebiotechnology
TEAM | LARA HOTH | VERSANT VENTURES History. Prior to joining Versant in 2016, Lara spent six years at Novartis and held controller roles at two other companies. Lara began her career at PricewaterhouseCoopers, initially in the assurance group and later in management consulting. She received her Bachelor of AMIRA PHARMACEUTICALS Amira Pharmaceuticals, until its acquisition, was a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. TEAM | JEREMY CALDWELL, PH.D. | VERSANT VENTURES Prior to joining Merck in 2008, Jeremy was the executive director of molecular and cellular biology, lead discovery and genomics at the Genomics Institute of the Novartis Research Foundation (GNF). Jeremy received a B.S. in molecular and cellular biology from the University of California at Berkeley and a Ph.D. in molecular pharmacology fromVERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | VERSANT VENTURES | BRIAN ATWOOD | VERSANT VENTURES Brian Atwood is a Managing Director specializing in biotechnology investing at Versant. Prior to co-founding Versant, he spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. He also has more than 15 years of operating experience in thebiotechnology
TEAM | VERSANT VENTURES | WILLIAM LINK | VERSANT VENTURES Background. Bill Link, Ph.D., is a co-founder of Versant, and a pioneer and leader of the highly successful ophthalmology venture category. Over his investing career, Bill has seen exits totaling more than $2B in combined enterprise value and was also named to the 2011Forbes Midas list.
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. TEAM | LARA HOTH | VERSANT VENTURES History. Prior to joining Versant in 2016, Lara spent six years at Novartis and held controller roles at two other companies. Lara began her career at PricewaterhouseCoopers, initially in the assurance group and later in management consulting. She received her Bachelor of TEAM | MARCELO BIGAL, M.D., PH.D. | VERSANT VENTURES Marcelo is a venture partner as well as CEO of Ventus, a Versant-backed company that is in stealth mode. He brings more than 13 years of pharmaceutical experience with a focus on neurology, spanning R&D, medical and scientific affairs. He has extensive experience in leading large and small scientific groups.REBECCA ROBERTSON
History. Before co-founding Versant, Beckie was a general partner at Institutional Venture Partners (IVP). From 1994-1996, Beckie served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the $200 million Critical Care business unit. In addition, Beckie was Vice President of AMIRA PHARMACEUTICALS Amira Pharmaceuticals, until its acquisition, was a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.858 THERAPEUTICS
858 Therapeutics is a stealth company based in San Diego. Company Name 858 Therapeutics. Location San Diego, CAVERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
MATTERHORN BIOSCIENCES Matterhorn is a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins. TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. OFFICES | VERSANT VENTURES Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
VERSANT VENTURES
Outcome. In December 2014, Northern Biologics officially launched with $45 million in committed funding from Versant and Celgene, secure foundational IP licenses, a well-developed R&D plan and the basis for a strong management and scientific team. In December 2016, the Versant team enabled Northern Biologics to execute a transformative deal TEAM | VERSANT VENTURES | WILLIAM LINK | VERSANT VENTURES Background. Bill Link, Ph.D., is a co-founder of Versant, and a pioneer and leader of the highly successful ophthalmology venture category. Over his investing career, Bill has seen exits totaling more than $2B in combined enterprise value and was also named to the 2011Forbes Midas list.
TEAM | VERSANT VENTURES | BRIAN ATWOOD | VERSANT VENTURES Brian Atwood is a Managing Director specializing in biotechnology investing at Versant. Prior to co-founding Versant, he spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. He also has more than 15 years of operating experience in thebiotechnology
NOVIRA THERAPEUTICS
Novira Therapeutics Inc. is focused on the discovery and development of first-in-class therapies for the treatment of chronic hepatitis B (CHB) infection, a global disease with a high level of unmet medicalneed.
TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
TEAM | PAUL GRAYSON | VERSANT VENTURES Background. Paul joined Versant in 2018. In addition to his reputation as a deal-maker, Paul brings a wealth of operating and investment experience from a successful career in the biotech sector spanning 25 years. He specializes in start-up through IND enablement, CMC andclinical proof of
TEAM | RACHEL LANE, PH.D. | VERSANT VENTURES Rachel is a Principal based in Versant’s San Francisco office. She is a neurobiologist by training with more than 10 years of experience sourcing new opportunities and leading transactions in business development and portfolio strategy roles across the biotech industry.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. OFFICES | VERSANT VENTURES Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
VERSANT VENTURES
Outcome. In December 2014, Northern Biologics officially launched with $45 million in committed funding from Versant and Celgene, secure foundational IP licenses, a well-developed R&D plan and the basis for a strong management and scientific team. In December 2016, the Versant team enabled Northern Biologics to execute a transformative deal TEAM | VERSANT VENTURES | WILLIAM LINK | VERSANT VENTURES Background. Bill Link, Ph.D., is a co-founder of Versant, and a pioneer and leader of the highly successful ophthalmology venture category. Over his investing career, Bill has seen exits totaling more than $2B in combined enterprise value and was also named to the 2011Forbes Midas list.
TEAM | VERSANT VENTURES | BRIAN ATWOOD | VERSANT VENTURES Brian Atwood is a Managing Director specializing in biotechnology investing at Versant. Prior to co-founding Versant, he spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. He also has more than 15 years of operating experience in thebiotechnology
NEWS | STABLIX THERAPEUTICS LAUNCHES WITH $63 MILLION Jun 03, 2021 Stablix Therapeutics Launches with $63 Million Series A Financing. Download PDF. Media Contact Steve Edelson TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
TEAM | PAUL GRAYSON | VERSANT VENTURES Background. Paul joined Versant in 2018. In addition to his reputation as a deal-maker, Paul brings a wealth of operating and investment experience from a successful career in the biotech sector spanning 25 years. He specializes in start-up through IND enablement, CMC andclinical proof of
TEAM | RACHEL LANE, PH.D. | VERSANT VENTURES Rachel is a Principal based in Versant’s San Francisco office. She is a neurobiologist by training with more than 10 years of experience sourcing new opportunities and leading transactions in business development and portfolio strategy roles across the biotech industry.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. OFFICES | VERSANT VENTURES Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics, Graphite Bio, Jnana, 858 Therapeutics, VenatoRx andStablix.
VERSANT VENTURES
Outcome. In December 2014, Northern Biologics officially launched with $45 million in committed funding from Versant and Celgene, secure foundational IP licenses, a well-developed R&D plan and the basis for a strong management and scientific team. In December 2016, the Versant team enabled Northern Biologics to execute a transformative deal TEAM | VERSANT VENTURES | WILLIAM LINK | VERSANT VENTURES Background. Bill Link, Ph.D., is a co-founder of Versant, and a pioneer and leader of the highly successful ophthalmology venture category. Over his investing career, Bill has seen exits totaling more than $2B in combined enterprise value and was also named to the 2011Forbes Midas list.
TEAM | VERSANT VENTURES | BRIAN ATWOOD | VERSANT VENTURES Brian Atwood is a Managing Director specializing in biotechnology investing at Versant. Prior to co-founding Versant, he spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. He also has more than 15 years of operating experience in thebiotechnology
NEWS | STABLIX THERAPEUTICS LAUNCHES WITH $63 MILLION Jun 03, 2021 Stablix Therapeutics Launches with $63 Million Series A Financing. Download PDF. Media Contact Steve Edelson TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
TEAM | PAUL GRAYSON | VERSANT VENTURES Background. Paul joined Versant in 2018. In addition to his reputation as a deal-maker, Paul brings a wealth of operating and investment experience from a successful career in the biotech sector spanning 25 years. He specializes in start-up through IND enablement, CMC andclinical proof of
TEAM | RACHEL LANE, PH.D. | VERSANT VENTURES Rachel is a Principal based in Versant’s San Francisco office. She is a neurobiologist by training with more than 10 years of experience sourcing new opportunities and leading transactions in business development and portfolio strategy roles across the biotech industry.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in launching and investing in a number of Versant’s portfolio companies including Quentis, VenatoRx, Repare, Pandion, Jnana and Gotham. Carlo has been instrumental in establishing Versant’s presence in theNortheast
TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
NOVIRA THERAPEUTICS
Novira Therapeutics | Johnson & Johnson. Novira Therapeutics Inc. is focused on the discovery and development of first-in-class therapies for the treatment of chronic hepatitis B (CHB) infection, a global disease with a high level of unmet medical need.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in launching and investing in a number of Versant’s portfolio companies including Quentis, VenatoRx, Repare, Pandion, Jnana and Gotham. Carlo has been instrumental in establishing Versant’s presence in theNortheast
TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
NOVIRA THERAPEUTICS
Novira Therapeutics | Johnson & Johnson. Novira Therapeutics Inc. is focused on the discovery and development of first-in-class therapies for the treatment of chronic hepatitis B (CHB) infection, a global disease with a high level of unmet medical need.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
VERSANT VENTURES
Outcome. In December 2014, Northern Biologics officially launched with $45 million in committed funding from Versant and Celgene, secure foundational IP licenses, a well-developed R&D plan and the basis for a strong management and scientific team. In December 2016, the Versant team enabled Northern Biologics to execute a transformative deal TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios NEWS | STABLIX THERAPEUTICS LAUNCHES WITH $63 MILLION Jun 03, 2021 Stablix Therapeutics Launches with $63 Million Series A Financing. Download PDF. Media Contact Steve Edelson TEAM | VERSANT VENTURES | BRIAN ATWOOD | VERSANT VENTURES Brian Atwood is a Managing Director specializing in biotechnology investing at Versant. Prior to co-founding Versant, he spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. He also has more than 15 years of operating experience in thebiotechnology
TEAM | PAUL GRAYSON | VERSANT VENTURES Background. Paul joined Versant in 2018. In addition to his reputation as a deal-maker, Paul brings a wealth of operating and investment experience from a successful career in the biotech sector spanning 25 years. He specializes in start-up through IND enablement, CMC andclinical proof of
REBECCA ROBERTSON
History. Before co-founding Versant, Beckie was a general partner at Institutional Venture Partners (IVP). From 1994-1996, Beckie served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the $200 million Critical Care business unit. In addition, Beckie was Vice President of AMIRA PHARMACEUTICALS Amira Pharmaceuticals, until its acquisition, was a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in launching and investing in a number of Versant’s portfolio companies including Quentis, VenatoRx, Repare, Pandion, Jnana and Gotham. Carlo has been instrumental in establishing Versant’s presence in theNortheast
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. MATTERHORN BIOSCIENCES Matterhorn is a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins. TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
VERSANT VENTURES
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders. View Discovery Engines.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | PETER EMTAGE, PH.D. | VERSANT VENTURES Background. Peter joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and was promoted to Venture Partner in April 2021. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design LabsInc. (CDL), which
STABLIX THERAPEUTICS Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). TEAM | MARKUS ENZELBERGER, PH.D. | VERSANT VENTURES Markus is a partner located in Basel where he plays a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine. He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. TEAM | VERSANT VENTURES | CLARE OZAWA | VERSANT VENTURES Background. Clare Ozawa, Ph.D., became a Versant Managing Director in 2017 and leads investments in San Diego and the Bay Area. Clare previously oversaw strategic business operations for all Inception Sciences research sites across North America. During her tenure at Inception, she assumed leadership roles in the creation and managementof six
TEAM | VERSANT VENTURES | CARLO RIZZUTO | VERSANT VENTURES Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in launching and investing in a number of Versant’s portfolio companies including Quentis, VenatoRx, Repare, Pandion, Jnana and Gotham. Carlo has been instrumental in establishing Versant’s presence in theNortheast
TEAM | MAX EISENBERG | VERSANT VENTURES Prior to Versant, Max served as the first General Counsel and Chief Compliance Officer of Polaris Partners out of its San Francisco office. In this role, Max supported the firm in legal, compliance, investor relations, and operational matters, including leading the development of the firm’s operations infrastructure and navigating its registration with the SEC as a registered investment adviser. MATTERHORN BIOSCIENCES Matterhorn is a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins. TEAM | TOM FROHLICH | VERSANT VENTURES History. Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of productdevelopment
VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.VERSANT VENTURES
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. TEAM | VERSANT VENTURES | BRAD BOLZON | VERSANT VENTURES Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale),Speedel (sale
VERSANT VENTURES
Outcome. In December 2014, Northern Biologics officially launched with $45 million in committed funding from Versant and Celgene, secure foundational IP licenses, a well-developed R&D plan and the basis for a strong management and scientific team. In December 2016, the Versant team enabled Northern Biologics to execute a transformative deal TEAM | VERSANT VENTURES | ALEX MAYWEG | VERSANT VENTURES Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios NEWS | STABLIX THERAPEUTICS LAUNCHES WITH $63 MILLION Jun 03, 2021 Stablix Therapeutics Launches with $63 Million Series A Financing. Download PDF. Media Contact Steve Edelson TEAM | VERSANT VENTURES | BRIAN ATWOOD | VERSANT VENTURES Brian Atwood is a Managing Director specializing in biotechnology investing at Versant. Prior to co-founding Versant, he spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. He also has more than 15 years of operating experience in thebiotechnology
TEAM | PAUL GRAYSON | VERSANT VENTURES Background. Paul joined Versant in 2018. In addition to his reputation as a deal-maker, Paul brings a wealth of operating and investment experience from a successful career in the biotech sector spanning 25 years. He specializes in start-up through IND enablement, CMC andclinical proof of
REBECCA ROBERTSON
History. Before co-founding Versant, Beckie was a general partner at Institutional Venture Partners (IVP). From 1994-1996, Beckie served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the $200 million Critical Care business unit. In addition, Beckie was Vice President of AMIRA PHARMACEUTICALS Amira Pharmaceuticals, until its acquisition, was a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.* Home
* Discovery Engines
* Team
*
* Portfolio
* Offices
* News
HARNESSING THE POWER OF SCIENCE, GLOBALLY DELIVERING STRONG RESULTS SINCE 1999$3.2B
UNDER MANAGEMENT
33
IPOS
42
M&AS
View Portfolio
AN EXPERIENCED TEAM
100+
YEARS OF VC EXPERIENCE60+
YEARS OF PHARMA EXPERIENCE45+
YEARS OF BIOTECH EXPERIENCEView Team
FEET ON THE GROUND WHERE DISCOVERIES ARE MADE7
LOCATIONS
4
DISCOVERY ENGINES
30+
ACADEMIC PARTNERSHIPSView Locations
OUR DISCOVERY ENGINES Versant’s Discovery Engines comprise in-house teams of scientists working in state of the art laboratory facilities to independently validate novel academic discoveries as the potential foundation for anew company.
View Discovery Engines* LP Access
* News
* Contact Us
* Site Map
* Privacy
* Terms
2019 Versant Ventures. a FINE site.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0